ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of “Buy” by Analysts

ProQR Therapeutics (NASDAQ:PRQR) has been given an average recommendation of “Buy” by the eight analysts that are covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $8.00.

Several research firms recently weighed in on PRQR. Citigroup upgraded ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Monday, March 10th. Cantor Fitzgerald initiated coverage on ProQR Therapeutics in a report on Tuesday, April 29th. They issued an “overweight” rating and a $8.00 target price on the stock. HC Wainwright increased their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, March 14th. Evercore ISI started coverage on ProQR Therapeutics in a research report on Tuesday, April 29th. They issued an “outperform” rating and a $5.00 price target for the company. Finally, Oppenheimer dropped their price target on shares of ProQR Therapeutics from $15.00 to $9.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th.

ProQR Therapeutics Price Performance

NASDAQ:PRQR opened at $1.81 on Thursday. The firm’s 50-day moving average price is $1.49 and its 200-day moving average price is $2.16. The company has a market capitalization of $190.44 million, a PE ratio of -5.66 and a beta of 0.35. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. The business had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $4.90 million. Equities analysts anticipate that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

Institutional Trading of ProQR Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Affinity Asset Advisors LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter valued at $7,486,000. Northern Trust Corp raised its position in ProQR Therapeutics by 2,550.1% in the 4th quarter. Northern Trust Corp now owns 417,398 shares of the biopharmaceutical company’s stock worth $1,106,000 after buying an additional 401,648 shares during the last quarter. Millennium Management LLC lifted its stake in ProQR Therapeutics by 1,864.4% during the 4th quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company’s stock valued at $7,492,000 after acquiring an additional 2,683,351 shares during the period. Woodline Partners LP bought a new position in ProQR Therapeutics during the 4th quarter valued at about $9,426,000. Finally, M&T Bank Corp purchased a new stake in shares of ProQR Therapeutics during the 4th quarter valued at about $330,000. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).